

## FORM 7

### MONTHLY PROGRESS REPORT

Name of Listed Issuer: Relay Medical Corp (formerly ChroMedX Corp. (the "Issuer")).

Trading Symbol: RELA

Number of Outstanding Listed Securities: 113,187,190

Date: April 9, 2019

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

## Report on Business

**1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

The Company continued with the expansion of its business into a Medtech incubator/accelerator platform after launching with a new Company name of Relay Medical Corp in late June 2018.

The Company has developed two proprietary software applications. Development and implementation of the software was conducted to provide a rapid prototyping platform and a proprietary developer toolkit, improve efficiencies and regulatory management for the advancement of the HemoPalm project. The software now acts as a backbone for the Company's multi-project development processes.

Relay introduced the Company's Pharmatrac Technology, Pharmatrac, a user experience centric system designed to improve management and identification of medications. The Pharmatrac technology was acquired as part of Relay's recent acquisition of the Ottawa Ontario based UX Data Sciences Corp. (UXD). Following the acquisition Relay Medical has completed the integration of UXD's technologies, development infrastructure and personnel. The Company commenced user studies on the Pharmatrac system in November.

Relay Medical continues to develop and productize multiple products and projects concurrently as well as vet strategic acquisitions that are complimentary to current infrastructure assets. Relay is now concurrently developing the HemoPalm platform, the recently announced UX Data Sciences products suite and is actively engaging in various discussions and negotiations regarding the expansion of Relay's technology portfolio.

**2. Provide a general overview and discussion of the activities of management.**

Management continued to be involved in the expansion of its business into a Medtech incubator/accelerator platform as detailed in 1. Above.

Management was focused on the formation and go-public activities relating to Glow LifeTech Ltd. Glow Lifetech is currently a private company founded by Relay and AgraFlora Organics International Inc. in December 2018 to develop technologies to service the rapidly growing global cannabis sector. In early April 2019, the Partners jointly announced the signing of a binding letter of intent ("LOI") to bring Glow public and announced the transfer of technology into Glow LifeTech Ltd.

The Issuer's management continued to be active with ongoing development and advancement of the HemoPalm project and the UX Data Sciences products suite as well as continued due diligence on various other projects and opportunities.

**3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

HemoPalm system design parameters have been enhanced to address both market needs and those of potential exit partners. Relay's new HemoPalm system design reflects a "complete healthcare enterprise solution" approach that addresses integration with existing hospital infrastructure, workflow, and regulatory requirements and includes flexibility to meet the needs of a wide range of users and applications.

Some of the notable product design and technology advancements include:

- Design and architecture of cartridge: Significant improvements were made in the design and architecture of the cartridge to improve high volume manufacturability and to reduce the cost of manufacturing and the cost of ownership. A low disposable cartridge cost is one of the key criteria for exit partners in selecting new technologies.
- Analyzer and System Design: The output of market analysis and consultation has allowed the further development of product design specifications for the analyzer and supporting system components in order to achieve optimal form and function in a complete "enterprise" solution.
- Co-oximetry: Analytical strategies have been developed to overcome the challenges of direct measurement of whole blood samples, with excellent results from preliminary "challenging" test samples.
- Sample Introduction: As the product is being developed to be used in multiple settings, with varying user skill sets, ease of use is critical and has been a focus of Relay's development team. Improvements to simplify the introduction of blood samples to the device have been incorporated into the latest cartridge design.
- Additionally, the Company has engaged with counsel and industry advisors to further optimize intellectual property protection, both as a core asset and as blocking IP against larger competitors who might desire to incorporate the HemoPalm technology into their product offerings.

**4. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**

None in the month of March 2019.

**5. Report on any labour disputes and resolutions of those disputes if applicable.**

None in the month of March 2019.

- 6. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**  
None in the month of March 2019.
- 7. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**  
None in the month of March 2019.
- 8. Provide details of any securities issued and options or warrants granted.**  
None in the month of March 2019.
- 9. Provide details of any loans to or by Related Persons.**  
None in the month of March 2019.
- 10. Provide details of any changes in directors, officers or committee members.**  
Messrs. Sid Thomas, Medhanie Tekeste and Greg Van Staveren were appointed to the Company's Board of Directors. George Langdon, Richard Janeczko and W. Clark Kent resigned from the Board.
- 11. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**  
There are no regulatory or political trends that affect the issuer. There is a trend to growth in the medical Point of Care market.

## Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated April 9, 2019.

Lahav Gil

**Name of Director or Senior  
Officer**

*"Lahav Gil"*  
**Signature**

Chief Executive Officer  
**Official Capacity**

<b>Issuer Details</b> Name of Issuer Relay Medical Corp.	For Month End March 31, 2019	Date of Report YY/MM/D 2019/04/09
Issuer Address Suite 1600, 400 Bay St.		
City/Province/Postal Code Toronto, ON M5H 2M5	Issuer Fax No. 1-844-247-6633	Issuer Telephone No. 647-872-9982
Contact Name W. Clark Kent	Contact Position President	Contact Telephone No. 647-872-9982
Contact Email Address ckent@relaymedical.com	Web Site Address <a href="https://www.relaymedical.com/">https://www.relaymedical.com/</a>	